Literature DB >> 16110017

Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial.

Søren M Bentzen1, Beste M Atasoy, Frances M Daley, Stanley Dische, Paul I Richman, Michele I Saunders, Klaus R Trott, George D Wilson.   

Abstract

PURPOSE: Accelerated repopulation is a main reason for locoregional failure after fractionated radiotherapy for head and neck squamous cell carcinoma (HNSCC). Epidermal growth factor receptor (EGFR) is a key controller of cellular proliferation in HNSCC, which stimulated the current study to look for a direct link between EGFR status and a possible clinical advantage of accelerated radiotherapy. PATIENTS AND METHODS: Immunohistochemical staining for EGFR was performed in 304 patients with available pretreatment tumor biopsy material among 918 patients randomized to receive continuous hyperfractionated accelerated radiotherapy versus conventionally fractionated radiotherapy. The EGFR index was estimated as the proportion of tumor cells with EGFR membrane staining.
RESULTS: Significant benefit in locoregional tumor control from continuous hyperfractionated accelerated radiotherapy was seen in patients with HNSCC with high EGFR expression (2P = .010) but not in those with low EGFR expression (2P = .85). EGFR status had no significant effect on survival or rate of distant metastases. The EGFR index was significantly associated with histologic grade and microvessel density. There was moderate support for an association between EGFR status and subsite within the head and neck region but no significant association with Ki-67 index, Ki-67 pattern, p53 index, p53 intensity, bcl-2 expression, or cyclin D1 index.
CONCLUSION: This study indicates a key role for the EGFR receptor in determining the proliferative cellular response to fractionated radiotherapy in HNSCC. It also shows that we can select the dose-fractionation regime that has the greatest chance of benefiting the patient. These results also encourage further development of EGFR targeting combined with fractionated radiotherapy in HNSCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16110017     DOI: 10.1200/JCO.2005.06.411

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  72 in total

Review 1.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

2.  From anatomical to biological target volumes: the role of PET in radiation treatment planning.

Authors:  D A X Schinagl; J H A M Kaanders; W J G Oyen
Journal:  Cancer Imaging       Date:  2006-10-31       Impact factor: 3.909

Review 3.  Integrating radiotherapy with epidermal growth factor receptor antagonists and other molecular therapeutics for the treatment of head and neck cancer.

Authors:  Juliette Thariat; Luka Milas; K Kian Ang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2007-11-15       Impact factor: 7.038

Review 4.  Stereotactic body radiotherapy for oligo-recurrence within the nodal area from colorectal cancer.

Authors:  Young Seok Seo; Mi-Sook Kim; Hyung-Jun Yoo; Won-Il Jang
Journal:  World J Gastroenterol       Date:  2014-02-28       Impact factor: 5.742

5.  Clinical radiobiology of head and neck cancer: the hypothesis of stem cell activation.

Authors:  P Pedicini; R Caivano; A Fiorentino; L Strigari
Journal:  Clin Transl Oncol       Date:  2014-12-09       Impact factor: 3.405

6.  Effect of erlotinib on epidermal growth factor receptor and downstream signaling in oral cavity squamous cell carcinoma.

Authors:  Christina I Tsien; Mukesh K Nyati; Aarif Ahsan; Susmita G Ramanand; Douglas B Chepeha; Francis P Worden; Joseph I Helman; Nisha D'Silva; Carol R Bradford; Gregory T Wolf; Theodore S Lawrence; Avraham Eisbruch
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

7.  Prevalence and predictive role of p16 and epidermal growth factor receptor in surgically treated oropharyngeal and oral cavity cancer.

Authors:  Shamir P Chandarana; Julia S Lee; Eric J P Chanowski; Assuntina G Sacco; Carol R Bradford; Gregory T Wolf; Mark E Prince; Jeffrey S Moyer; Avraham Eisbruch; Francis P Worden; Thomas J Giordano; Bhavna Kumar; Katrina G Cordell; Thomas E Carey; Douglas B Chepeha
Journal:  Head Neck       Date:  2012-08-21       Impact factor: 3.147

8.  Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount.

Authors:  Vladimir Tolmachev; Daniel Rosik; Helena Wållberg; Anna Sjöberg; Mattias Sandström; Monika Hansson; Anders Wennborg; Anna Orlova
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-17       Impact factor: 9.236

9.  Experience with combination of cetuximab plus intensity-modulated radiotherapy with or without chemotherapy for locoregionally advanced nasopharyngeal carcinoma.

Authors:  Xiaoshuang Niu; Chaosu Hu; Lin Kong
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-24       Impact factor: 4.553

10.  MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer.

Authors:  George Fountzilas; Anna Kalogera-Fountzila; Sophia Lambaki; Ralph M Wirtz; Angelos Nikolaou; Georgia Karayannopoulou; Mattheos Bobos; Vassiliki Kotoula; Samuel Murray; Alexandros Lambropoulos; Gerasimos Aravantinos; Konstantinos Markou; Eleni Athanassiou; Despina Misailidou; Konstantine T Kalogeras; Demosthenis Skarlos
Journal:  J Oncol       Date:  2009-12-29       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.